Filing Details
- Accession Number:
- 0000950170-24-016712
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-02-16 21:48:16
- Reporting Period:
- 2024-02-14
- Accepted Time:
- 2024-02-16 21:48:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1609809 | Seres Therapeutics Inc. | MCRB | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1435744 | Thomas Desrosier | C/O Seres Therapeutics, Inc. 101 Cambridge Park Drive Cambridge MA 02140 | Chief Legal Officer And Evp | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-02-15 | 10,625 | $0.00 | 124,516 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-02-16 | 3,939 | $1.08 | 120,577 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2024-02-14 | 213,750 | $0.00 | 213,750 | $1.10 |
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2024-02-14 | 287,905 | $0.00 | 287,905 | $1.10 |
| Common Stock | Restricted Stock Units | Acquisiton | 2024-02-14 | 35,625 | $0.00 | 35,625 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2024-02-15 | 10,625 | $0.00 | 10,625 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 213,750 | 2034-02-13 | No | 4 | A | Direct | |
| 287,905 | 2034-02-13 | No | 4 | A | Direct | |
| 35,625 | No | 4 | A | Direct | ||
| 31,875 | No | 4 | M | Direct |
Footnotes
- Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
- The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.08 to $1.115, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The option will vest as to 25% of the shares on February 14, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
- The option will vest, if at all, in two substantially equal installments upon achievement of a 30-day trailing average public market closing price per share of the Issuer's common stock greater than or equal to $3.00 and $5.00, respectively.
- The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
- The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Billionaire Hedge Funds
